--- title: "Hong Kong Stock Movement: CF PHARMTECH surged 24.70%, as the approval of its new drug clinical application sparked market enthusiasm" type: "News" locale: "en" url: "https://longbridge.com/en/news/279189204.md" description: "CF PHARMTECH surged 24.70%; CSPC Pharmaceutical Group rose 1.98%, with a transaction volume of HKD 132 million; United Laboratories fell 2.98%, with a transaction volume of HKD 71.94 million; Hansoh Pharmaceutical dropped 0.67%, with a transaction volume of HKD 67.83 million; Heng Rui Medicine increased by 0.78%, with a market value of HKD 428.1 billion" datetime: "2026-03-16T02:07:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279189204.md) - [en](https://longbridge.com/en/news/279189204.md) - [zh-HK](https://longbridge.com/zh-HK/news/279189204.md) --- # Hong Kong Stock Movement: CF PHARMTECH surged 24.70%, as the approval of its new drug clinical application sparked market enthusiasm **Hong Kong Stock Movement** Changfeng Pharmaceutical surged 24.70%. Based on recent news, 1. On March 13, Changfeng Pharmaceutical announced that its self-developed inhalation powder ICF001 for the treatment of pulmonary arterial hypertension and interstitial lung disease-related pulmonary arterial hypertension has officially been accepted for clinical trial application by the National Medical Products Administration of China. This marks the acceleration of the company's innovative R&D pipeline in the high-end respiratory formulation field, driving a significant increase in stock price. 2. On March 16, Changfeng Pharmaceutical further announced that the first indication for ICF001 is arterial pulmonary hypertension and interstitial lung disease-related pulmonary arterial hypertension. This drug, developed based on a prodrug technology platform, is specifically designed for the treatment of pulmonary arterial hypertension and related severe lung diseases, with the market having high expectations for its clinical application, further boosting the stock price. The progress in innovative drug development is significant, and market expectations have risen. **Stocks with High Trading Volume in the Industry** Shiyao Group rose 1.98%. There has been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. no\_news United Pharmaceuticals fell 2.98%. Based on recent key news: 1. On March 12, United Pharmaceuticals issued a profit warning, expecting a profit of about 2 billion yuan in 2025, a decrease of 24.76% compared to 2024. The profit decline is mainly due to the drop in market prices of intermediate products and raw materials, leading to a decrease in profits in related segments. The profits in the formulation product segment increased by about 1.4 billion yuan, with approximately 1.3 billion yuan contributed by Novo Nordisk's licensing fee income, partially offsetting the profit decline in other segments. This news led to a drop in stock price. 2. On March 13, United Pharmaceuticals' stock opened down over 5%, and as of the time of writing, it fell 5.28% to HKD 12.2, with a trading volume of HKD 4.1724 million. The profit warning news triggered market concerns, leading to a continued decline in stock price. 3. On March 13, concerns about United Pharmaceuticals' future profitability intensified, leading to a decline in investor confidence and putting pressure on the stock price. The pharmaceutical industry is facing price pressures, which need attention. Hansoh Pharmaceutical fell 0.67%, with a trading volume reaching HKD 67.83 million, and there has been no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Market Capitalization in the Industry** Hengrui Medicine rose 0.78%. Based on recent key news: 1. On March 13, Hengrui Medicine's self-developed Class 1 innovative drug, Hecolin (Hecolin), received approval from the National Medical Products Administration for a new indication, suitable for patients aged 15 and above with newly diagnosed severe aplastic anemia. This news has boosted market confidence in the company's innovative drug development capabilities, driving the stock price up. 2. On March 13, a subsidiary of Hengrui Medicine received a clinical trial approval notice for liposomal irinotecan injection, which will conduct a Phase III clinical study for postoperative adjuvant treatment of pancreatic cancer. This move demonstrates the company's continued investment in the field of anti-cancer drugs, enhancing investor confidence On March 13, HengRui Medicine's application for the marketing authorization of Shudi Insulin Nulin Peptide Injection was accepted by the National Medical Products Administration, suitable for adults with type 2 diabetes who have poor blood sugar control. This progress indicates the company's expansion of its product line in the diabetes treatment field, further enhancing market expectations. The innovation in drug research and development in the pharmaceutical industry remains active ### Related Stocks - [02652.HK](https://longbridge.com/en/quote/02652.HK.md) ## Related News & Research - [Voicecomm Technology Enters HK$94 Million Share Sale Agreement](https://longbridge.com/en/news/282482425.md) - [Inhibikase Begins Pivotal Phase 3 Trial in PAH](https://longbridge.com/en/news/281886043.md) - [Nio Onvo to equip updated L90 SUV with in-house developed Shenji NX9031 chip](https://longbridge.com/en/news/282405215.md) - [AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial](https://longbridge.com/en/news/282408747.md) - [Cloud Factory Technology, Directors Censured by Hong Kong Bourse Over Disclosure Discrepancies](https://longbridge.com/en/news/282689380.md)